$Femasys(FEMY.US$ 8k report: On June 20, 2024, Femasys Inc., a biomedical company specializing in women's health, announced the receipt of CE Mark approval for four of its products, enabling the start of commercialization efforts in Europe. The approved products, which include FemaSeed, FemVue, FemCerv, and FemCath, comply with the European Union Medical Device Regulation (EU MDR). This regulatory milestone follows the company's recent completion of its commercial team in the United States and ...
1
$Banzai International (BNZI.US)$ be careful they don't excute the Public offering shares sells yet. .18